announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma…
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced preliminary clinical data as of September 25, 2025, the preliminary data cutoff from its ongoing…
a biotechnology company focused on developing next-generation therapeutic antibodies, and Chime Biologics, a global leading contract development and manufacturing organization (CDMO), today announced a strategic collaboration for the development of SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease (IBD), with…
a world leader in neutralizing GDF-15 in cancer and cachexia, today announced updated long-term data from its ongoing GDFATHER-1/2a trial (NCT04725474) at the European Society of Medical Oncology (ESMO) Congress 2025. The data provide further evidence that Growth Differentiation Factor-15…
For decades, traditional adrenaline auto-injectors (AAIs) have been the only available treatment for anaphylaxis—a life-threatening allergic reaction.1,2 Yet from today, the UK’s first needle-free emergency anaphylaxis treatment, the EURneffy® nasal adrenaline spray, is available on prescription.3 EURneffy® 2 mg nasal spray offers a…
the AI precision oncology company behind the Polaris™ platform, today announced its selection for the Memorial Sloan Kettering (MSK) iHub Challenge 2025 Cohort program. This engagement will provide StratifAI with access to MSK’s extensive clinical datasets and the opportunity to…
(Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced, the study met…
Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of new data from its Phase 1 study of IKS014, a human epidermal growth factor receptor 2 (HER2)-directed ADC, in patients with advanced HER2+…
DATROWAY® Demonstrates Significant Survival Benefit Over Chemotherapy in First-Line Metastatic Triple-Negative Breast Cancer in TROPION-Breast02 Trial Positive results from the pivotal TROPION-Breast02 phase 3 trial have shown that DATROWAY® (datopotamab deruxtecan) delivers a statistically significant and clinically meaningful improvement in…
Delcath Systems, Inc. Reports Promising Phase 2 CHOPIN Trial Results for Liver-Dominant Metastatic Uveal Melanoma Delcath Systems, Inc. (NASDAQ: DCTH), a pioneering interventional oncology company focused on liver-directed therapies for primary and metastatic liver cancers, today announced the results of…